Informative gene network for chemotherapy-induced peripheral neuropathy by Cielito C. Reyes-Gibby et al.
BioData Mining
Reyes-Gibby et al. BioData Mining  (2015) 8:24 
DOI 10.1186/s13040-015-0058-0RESEARCH Open AccessInformative gene network for
chemotherapy-induced peripheral neuropathy




Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA
Full list of author information is
available at the end of the articleAbstract
Background: Host genetic variability has been implicated in chemotherapy-induced
peripheral neuropathy (CIPN). A dose-limiting toxicity for chemotherapy agents, CIPN
is also a debilitating condition that may progress to chronic neuropathic pain. We
utilized a bioinformatics approach, which captures the complexity of intracellular and
intercellular interactions, to identify genes for CIPN.
Methods: Using genes pooled from the literature as a starting point, we used
Ingenuity Pathway Analysis (IPA) to generate gene networks for CIPN.
Results: We performed IPA core analysis for genes associated with platinum-,
taxane- and platinum-taxane–induced neuropathy. We found that IL6, TNF, CXCL8,
IL1B and ERK1/2 were the top genes in terms of the number of connections in
platinum-induced neuropathy and TP53, MYC, PARP1, P38 MAPK and TNF for
combined taxane-platinum–induced neuropathy.
Conclusion: Neurotoxicity is common in cancer patients treated with platinum
compounds and anti-microtubule agents and CIPN is one of the debilitating
sequela. The bioinformatic approach helped identify genes associated with CIPN
in cancer patients.Introduction
Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating condition. CIPN is
a dose-limiting toxicity for chemotherapy agents, such as oxaliplatin, cisplatin, and plat-
inum [1–4]. Chemotherapeutic agents may cause structural damage to peripheral nerves,
which can result in aberrant somatosensory processing by the peripheral and/or central
nervous system. The symptoms of CIPN vary depending on the type of chemotherapy ad-
ministered and which nerve fibers are affected. Unusual sensations (paresthesia), numb-
ness, balance problems or pain may result from chemotherapies that affect the sensory
nerve fibers. When motor nerves are affected, patients may report weakness of the mus-
cles in the feet and hands.
Patients who suffer from CIPN have a higher risk (as much as threefold higher) of
developing neuropathic pain (NP) [5]. Defined as “pain initiated or caused by primary
lesion or dysfunction in the nervous system,” NP occurs in nearly 40 % of patients who
experience cancer pain [6, 7]. Patients with NP experience higher pain intensity and
less effective control of their pain with conventional analgesia [8]. Further, patients
with NP rate their level of pain relief to be significantly lower than those with nocicep-
tive pain (defined as pain caused by activation of primary afferents in somatic or© 2015 Reyes-Gibby et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in
any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Reyes-Gibby et al. BioData Mining  (2015) 8:24 Page 2 of 23visceral tissues) in response to a single dose of an opioid [8, 9]. Patients with NP
report twice as many visits to their health care provider (p = 0.02) and take
more prescription (50 % versus 19 %; p = 0.001) and over-the-counter medications
(62.5 % versus 45 %; p = 0.08) for pain than those without NP [5].
Published guidelines for the initial treatment of NP include the use of gabapentin,
pregabalin, carbamazepine, tricyclic antidepressants, oxycodone, morphine, methadone,
tramadol, duloxetine, and venlafaxine [10, 11]. However, placebo-controlled trials have
shown that medications such as gabapentin [12] and glutamine [13] have no statistically
significant effects on NP. Animal and human studies have been conducted to identify
the best ways to treat and manage NP [14–20]. Because CIPN is a risk factor for the
development of NP in cancer patients, a better understanding of the potential biological
mechanisms underlying CIPN has huge clinical significance.
Host genetic variability has been implicated in many pain conditions, including neur-
opathy. Each of these studies assessed different therapeutic agents and different genetic
mechanisms. However, it is understood that as a complex trait, several genes are impli-
cated in CIPN. Bioinformatics provides tools for using large-scale information to pro-
duce comprehensive networks of genes and the underlying biological pathways
implicated in a phenotype. Therefore, in this study, we used the Ingenuity Pathway
Analysis (IPA), a bioinformatic tool for analyzing biological data, and performed a com-
prehensive network-based approach to identify genes implicated in neuropathy induced
by chemotherapy agents. Compared to traditional regression approaches, network-
based approaches can provide a holistic picture that captures the complexity of intra-
cellular and intercellular interactions in diseases [21]. Furthermore, the network-based
approaches can identify genes and pathways related to a disease or phenotype, which
will lead to a better understanding of the underlying biological mechanisms [22]. Fur-
ther, networks generated from IPA core analysis may suggest new candidate genes for
future studies of CIPN.Methods
With the goal of identifying a comprehensive list of genes and potentially novel genes
associated with CIPN, we first conducted a literature search as described below. Using
genes pooled from the literature as a starting point, we used IPA to generate gene net-
works for CIPN.Literature review
Using the PubMed database, we performed a comprehensive literature review, limiting
our search to human studies and articles published in English before July 2014. The pri-
mary purpose of the literature search was to identify genes associated with CIPN in cancer
patients. The terms we used were “cancer neuropathy SNP,” “cancer neuropathy SNPs,”
“cancer neuropathy gene,” “cancer neuropathy genes,” “cancer neurotoxicity SNP,” “cancer
neurotoxicity SNPs,” “cancer neurotoxicity gene” and “cancer neurotoxicity genes.” We
then screened the resulting articles based on the title, abstract, and the full text, and ex-
cluded duplicate articles. Next, we manually searched the reference lists of the articles
identified in our initial search and those in related review articles to identify additional
relevant articles (Table 1). From these studies, we retrieved the information about genes
Table 1 Number of articles obtained using different search terms
Search terms # of articles by PubMed
search
# of articles by initial
screen






30 20 36 56
cancer neuropathy
genes(gene)
266 1 0 1
cancer neurotoxicity
SNPs(SNP)
37 6 0 6
cancer neurotoxicity
genes(gene)
349 1 0 1
Total 682 28 36 64
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and included those genes in the IPA. In particular, we included only those genes for IPA
analysis that (1) have been replicated in an independent study or meta-analysis, (2) have
at least one SNP that reached the genome-wide significance level, or (3) have a known
biological functional significance (e.g., multi-drug resistance, drug metabolism, and medi-
ating developmental events in the nervous system). We also summarized the information
based on the different chemotherapy agents used for cancer patients.Ingenuity pathway analysis
IPA (Ingenuity® Systems, www.ingenuity.com) is a software that connects a list of mole-
cules in a set of networks based on the scientific information contained in the Ingenu-
ity Knowledge Base of biological interactions and functional annotations from millions
of relationships between proteins, genes, complexes, cells, tissues, drugs, and diseases
[23, 21]. In the networks, nodes are used to represent molecules (e.g., genes, chemicals,
protein families, complexes, microRNA species and biological processes) [24] and lines
connecting two molecules are used to represent the relationship between them. Many
different types of relationships are considered in the IPA analyses, including activation,
binding, causation, chemical-chemical interaction, expression enzyme catalysis, inhib-
ition, biochemical modification, protein-protein binding and transcription.
In this study, we utilized the IPA core analysis function to generate relevant networks
that identify additional genes that interact with the genes identified from the literature
review (denoted as focus genes in IPA). The IPA core analysis function is a process to
create networks on the basis of the focus genes [25]. The working hypothesis for net-
work generation is that the biological function involves locally dense interactions; thus,
IPA uses an algorithm to attempt to generate networks that are as densely connected
as possible [26]. The network generation process first ranks the focus genes in decreas-
ing order on the basis of triangular connectivity, which measures the number of tri-
angular connections in which a gene functions (or pairs of genes to which a gene is
connected). The most connected focus gene (the top ranked gene) is considered to be
the starting seed gene. Next, the remaining focus genes that are in the neighborhood of
the starting seed gene are added to generate the first seed gene network. A neighbor-
hood is defined as a gene plus the genes exactly one connection away from that gene.
Then the second seed gene network is identified from the focus genes that are not in-
cluded in the first seed gene network. The process continues until all focus genes are
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make larger networks by connecting seed gene networks through an additional non-
focus gene. If the gene network does not reach the maximum network size (140 genes
in this study), IPA will then connect additional genes/networks from its database to any
of the genes involved in the gene network. Specifically, given a network, to identify add-
itional genes to be added, IPA gives priority to the genes that have the largest overlap
with the existing network and have the least number of neighbors. This property is
measured using a metric called specific connectivity, which is calculated by divid-
ing the number of genes in the intersection of the neighborhood and the existing
network by the union of the number of genes in the neighborhood and the exist-
ing network. The gene with the highest specific connectivity score is included in
the existing network. Importantly, the IPA analysis can exclude a focus gene from
the resulting network if such a gene is less likely to have connections (i.e., bio-
logical relationships) with the network.
The resulting functions/pathways/networks are evaluated using the right-tailed Fish-
er’s exact test, which provides p values based on the null hypothesis that the association
between a set of focus genes and a given function/pathway/network is due to random
chance [25]. Specifically, if the final network includes n genes and nf of them are focus
genes, the p value is the probability of finding nf or more focus genes in a set of n genes
randomly selected from the IPA pre-specified database [26]. A score, which is assessed
as -log10(p value), is used to rank the resulting functions/pathways/networks. We used
a significance level of <10−5 in our study (score > 5) when selecting networks [21].
We limited the IPA analysis to human studies. In the IPA core analysis, we used the
Ingenuity Knowledge Base as the reference set. In order to generate networks in the
core analysis, we used the settings of a maximum of 140 genes per network and 25 net-
works per analysis, because the networks for up to 140 genes allow for the possibility
that the same network can include all focus genes [27]. We reported the most intercon-
nected genes in the networks as the key genes of interest, because highly connected
molecules (called hubs) are typically associated with biological functions or diseases
[22, 24, 21, 26, 27].Results
Literature review
From our search of the PubMed database, we initially identified 682 articles. After
screening the title, abstract and full text, we excluded 654 articles for the following rea-
sons (Table 1): (1) not human studies; (2) not published in English; (3) meta-analysis
study, review or letter to the editor; (4) clinical trial studies; (5) not genetic association
studies; (6) not neuropathy-related phenotypes studies; (7) not cancer studies; and (8)
duplicate articles from different searches. We then manually searched the reference
lists from the resulting 28 articles and from related review articles about genetic neur-
opathy studies, and identified 36 more articles. As a result, we had a total of 64 articles
from which we extracted information to identify the focus genes and perform the ana-
lyses through IPA.
Table 2 lists the information we retrieved from each of the studies, including the year
of publication, first author, ethnicity of patient population, cancer type, sample size,
Table 2 List of genetic association studies for chemotherapy-induced neuropathy in cancer
patients, sorted by publication year and name of first author
Year First author Ethnicity Cancer type Sample
size
Phenotype Significant genes








2004 Isla D [42] W Lung 62 Docetaxel-cisplatin-
treated neurological
None






2006 Sissung TM [44] W N/A 26 Paclitaxel-induced
neuropathy
ABCB1
2007 Gamelin L [45] W Colon, rectum 145 Oxaliplatin-induced
neurotoxicity
AGXT
2007 Marsh S [46] N/A Ovarian 914 Paclitaxel/docetaxel-
induced neuropathy
None





2007 Ruzzo A [48] W Colorectal 166 Oxaliplatin-induced
neurotoxicity
GSTP1
2008 Keam B [49] A Gastric 73 Peripheral sensory
neuropathy
None




2008 Sissung TM [51] N/A Prostate 73 Docetaxel-induced
neuropathy
ABCB1




2009 Goekkurt E [53] W Gastric 134 Neurotoxicity GSTP1
2009 Green H [54] W Ovarian 38 Sensory/motor
neuropathy
None




2009 Kweekel DM [56] W Colorectal 91 Neurotoxicity None






2009 Seo BG [58] A Gastric 94 Neuropathy None
2010 Antonacopoulou
AG [59]
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Table 2 List of genetic association studies for chemotherapy-induced neuropathy in cancer
patients, sorted by publication year and name of first author (Continued)








2010 Khrunin AV [65] W Ovarian 104 Cisplatin-based
neuropathy
GSTM1, GSTM3
2010 Li QF [66] A Gastric 92 Neurological
toxicity
GSTP1

























W Ovarian 119 Sensory neuropathy None
2011 Bergmann TK
[72]
W Ovarian 92 Sensory neuropathy None
































2011 Hong J [77] A Colorectal 52 Sensory neuropathy GSTP1








2011 Leskela S [79] W Lung, breast,
ovary, uterus,
head and neck
118 Neurotoxicity CYP2C8, CYP3A5
2011 Sucheston LE
[80]
W, AA Breast 888 Taxane-induced
neurotoxicity
FANCD2
2012 Baldwin RM [81] W, AA,
A
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Table 2 List of genetic association studies for chemotherapy-induced neuropathy in cancer
patients, sorted by publication year and name of first author (Continued)


















































W Ovarian 241 Paclitaxel induced
neuropathy
None
2013 Cecchin E [90] W Colorectal 144 Oxaliplatin
neurotoxicity
ABCC1, ABCC2








2013 Hertz DL [92] W, AA Breast 209 Paclitaxel-induced
neuropathy
CYP2C8

















2013 Lee KH [95] A Colon 292 Sensory neuropathy XRCC1





















2014 Bhojwani D [100] N/A 369 ASTN2, PXDC1, IYD
Reyes-Gibby et al. BioData Mining  (2015) 8:24 Page 7 of 23
Table 2 List of genetic association studies for chemotherapy-induced neuropathy in cancer

















2014 Khrunin AV [103] W Ovarian 104 Cisplatin-based
neurotoxicity
None






W: White; A: Asian; AA: African American; H: Hispanic
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patients of different ethnic groups. Neuropathy (or neurotoxicity) in cancer patients
is usually induced by the chemotherapy agents used in cancer treatment, such as
oxaliplatin, cisplatin, and platinum, and is usually measured according to the
National Cancer Institute’s Common Terminology Criteria for Adverse Events or
Common Toxicity Criteria.
In Table 3, we summarize the focus genes from the literature review with respect to
neuropathy induced by different chemotherapy agents, including platinum, taxane, plat-
inum/taxane, Bortezomib, bortezomib/vincristine, thalidomide, methotrexate, cytara-
bine, platinum/fluorouracil, platinum/S-1 (i.e., oral fluoropyrimidine consists of tegafur,
5-chloro-2,4 dihydroxypyrimidine, and potassium oxonate), taxane/gemcitabine, plat-
inum/fluorouracil/leucovorin, platinum/fluorouracil/irinotecan, prednisone/vincristine/
methotrexate, platinum/capecitabine, platinum/fluorouracil/irinotecan/leucovorin and
rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone. Among the different
(or combined) chemotherapy agents, those studied most frequently in relation to drug-
induced neuropathy were platinum, taxane and the combination of platinum/taxane,
for which our literature search respectively produced 21, 19 and 5 related papers.
Among the focus genes reported in the articles, GSTP1, CYP2C8 and ABCB1 were stud-
ied the most frequently (Table 4). ABCC2 and GSTP1 were associated with both plat-
inum- and taxane-induced neuropathy; CYP2C8 was associated with both taxane- and
platinum/taxane-induced neuropathy; and ERCC1 was associated with platinum- and
platinum/taxane-induced neuropathy. Besides platinum-, taxane- and platinum/taxane-
induced neuropathy, neuropathy induced by other chemotherapy agents were not fre-
quently studied. Therefore, we focused on the genes associated with platinum-, taxane-
and platinum/taxane-induced neuropathy in our analyses.
IPA core analysis
We performed the IPA core analysis for the focus genes reported to be associated with
platinum-, taxane- and platinum/taxane- induced neuropathy. The significant networks
revealed from the IPA core analyses are shown in Figs. 1, 2 and 3 for the focus genes
Table 3 Summary of genes associated with chemotherapy agent-specified neuropathy from the
literature review. Number of papers for each agent-specified neuropathy, number of genes
associated with each agent-specified neuropathy and number of agent-specified neuropathies
associated with each gene are shown. For the association between a gene and an agent-specified
neuropathy, the number of relating papers is listed















26 19 7 7 17 6 3 1 1 1 1 2 1 2 0 0 0
# of
agents
GSTP1 6 7 1 1 1 1 1






























CYP3A4 2 1 1
CYP3A5 2 1 1
ABCG1 1 1
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Table 3 Summary of genes associated with chemotherapy agent-specified neuropathy from the
literature review. Number of papers for each agent-specified neuropathy, number of genes
associated with each agent-specified neuropathy and number of agent-specified neuropathies
associated with each gene are shown. For the association between a gene and an agent-specified
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Table 3 Summary of genes associated with chemotherapy agent-specified neuropathy from the
literature review. Number of papers for each agent-specified neuropathy, number of genes
associated with each agent-specified neuropathy and number of agent-specified neuropathies
associated with each gene are shown. For the association between a gene and an agent-specified







P: Platinum; T: Taxane; P/T: Platinum/Taxane; B: Bortezomib; B/V: Bortezomib/Vincristine; Th: Thalidomide; M:
Methotrexate; Cyt: Cytarabine; P/F: Platinum/Fluorouracil; P/S: Platinum/S-1; T/G: Taxane/Gemcitabine; P/F/L: Platinum/
Fluorouracil/Leucovorin; P/F/I: Platinum/Fluorouracil/Irinotecan; Pr/V/M: Prednisone/Vincristine/Methotrexate; P/C:
Platinum/Capecitabine; P/F/I/L: Platinum/Fluorouracil/Irinotecan/Leucovorin;
R/Cyc/D/V/Pr: Rituximab/Cyclophosphamide/Doxorubicin/Vincristine/Prednisone
Table 4 Focus genes* associated with platinum-, taxane-, and platinum/taxane- induced
neuropathy, as identified through the literature review



























*Genes shown to be significant based on the literature
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Fig. 1 The most significant network (p value = 10−12) generated by IPA core analysis for 26 focus genes
associated with platinum-induced neuropathy. Green: focus genes; red: genes with at least 15 connections;
yellow: focus genes with at least 15 connections. Dashed and solid lines represent indirect and direct
interactions, respectively
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opathy, respectively. In the networks, the solid and dashed edges or arrows indicate direct
and indirect interactions, respectively. In Table 5, we report the genes that had at least 15
connections (i.e., hubs, suggesting biological importance) in the networks, ranked by the
number of connections for each gene.
Platinum-induced neuropathy
The IPA core analysis revealed six networks associated with platinum-induced neur-
opathy. Using a nominal significance level of 10−5, of the 6 networks, we found only one
network to be significant (p value of 10−12; Fig. 1. We note that 66 genes (one focus gene
and 65 “novel” genes) out of 121 genes in the network have at least 15 connections
(Table 5), suggesting the potential biological importance of these genes in CIPN associated
with platinum-based chemotherapy. The gene ITGB3 was the only focus gene in the net-
work, and the top 5 “novel” genes were IL6,TNF, CXCL8, IL1B and ERK1/2.
Taxane-induced neuropathy
The IPA core analysis for taxane-induced neuropathy revealed eight networks, two of
which were significant, with p values of 10−9 and 10−8 (Fig. 2). There is no hub in the
ab
Fig. 2 The most significant networks (p values = 10−9 and 10−8) generated by IPA core analysis for 19 focus
genes associated with taxane-induced neuropathy. Green: focus genes. Dashed and solid lines represent
indirect and direct interactions, respectively. a network 1 (p values = 10−9). b network 2 (p values = 10−8)
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with taxane-induced neuropathy.Platinum/taxane-induced neuropathy
The IPA core analysis for platinum/taxane-induced neuropathy identified three net-
works, one of which was significant, with a p value of 10−8 (Fig. 3). We note that 6
Fig. 3 The most significant network (p value = 10−8) generated by IPA core analysis for 7 focus genes
associated with platinum/taxane-induced neuropathy. Green: focus genes; red: genes with at least 15
connections; yellow: focus genes with at least 15 connections. Dashed and solid lines represent indirect
and direct interactions, respectively
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have at least 15 connections. The gene BCL2 is the only focus gene included in the net-
work that has more than 15 connections. The 5 additional genes that directly or indirectly
interact with the corresponding focus genes associated with platinum/taxane-induced
neuropathy based on the literature are TP53, MYC, PARP1, P38 MAPK and TNF.
Discussion
In this study, we performed a comprehensive literature review to identify genes impli-
cated in CIPN and then used IPA bioinformatic tools to conduct comprehensive path-
way and network analyses of the known genes identified in the literature. Neurotoxicity
is common in cancer patients who are treated with platinum compounds and anti-
microtubule agents, and the development of CIPN is a potentially debilitating sequela.
From the literature review, we found that neuropathy induced by platinum compounds
and taxanes (and a combination of these two agents) has been studied most frequently.
Neuropathy induced by chemotherapy agents other than platinum, taxane and plat-
inum/taxane combinations has not been adequately studied.
Among the focus genes identified from our literature search, GSTP1, CYP2C8 and
ABCB1 were most frequently assessed as candidates for CIPN. From the literature re-
view, we also found that the genomic variations of genes associated with neuropathy
Table 5 List of genes with at least 15 connections (i.e., hubs*) in the networks, ranked by the
number of connections for each gene
Platinum-induced CIPN Platinum/taxane-induced CIPN
IPA Symbol # of connections IPA Symbol # of connections
IL6 70 TP53 42
TNF 69 BCL2** 28
CXCL8 56 MYC 16
IL1B 55 PARP1 16
ERK1/2 54 P38 MAPK 15
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Table 5 List of genes with at least 15 connections (i.e., hubs*) in the networks, ranked by the
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ERCC1, ACYP2, FARS2, GSTM1 and TAC1 were found to be associated with platinum-
induced neuropathy in more than one study but were not associated with taxane-
induced neuropathy. On the other hand, CYP2C8, ABCB1, EPHA5, EPHA6 and
TUBB2A were found to be associated with taxane-induced neuropathy in more than
one study, but not to be associated with platinum-induced neuropathy (Table 3). The
overall theme is that these CIPN-associated genes are related to the networks that
regulate intracellular drug concentrations (e.g., GSTP1, GSTM1 and ABCB1), response
to DNA damage (e.g., ERCC1, FANCD2, BCL2, and SOX10), cellular stress response
pathways (e.g., BCL2), inflammation (e.g., ABCC1, ABCC2, ABCG2, ITGA1, ITGB3,
TAC1, ABCB1, ABCC2, EPHA4, EPHA6, SLCO1B1, TUBB2A, ABCA1, BCL2, OPRM1
and TRPV1), and neuronal plasticity (e.g., ERCC1 and TAC1).
We performed IPA core analysis for the genes associated with platinum-, taxane- and
platinum/taxane-induced neuropathy. We found that IL6, TNF, CXCL8, IL1B and ERK1/
2 were the top genes in terms of the number of connections in platinum-induced neur-
opathy, suggesting either direct or indirect interactions with nervous tissue leading to
CIPN after exposure to platinum compounds. It is particularly interesting that studies of
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IL6, TNF and IL1B polymorphisms. These studies hypothesized that cytokines associated
with inflammation or tissue damage modify the activity of nociceptors, which contributes
to pain hypersensitivity. Studies also suggest that hyperexcitability in pain transmission
neurons may also be caused by proinflammatory cytokines produced by glial cells that re-
spond to inflammation or other cancer-produced cytokines. Substance P and excitatory
amino acids released from presynaptic terminals result to an exaggerated pain response
[38, 39]. In patients with lung cancer, polymorphisms in TNF and IL6 were significantly
associated with pain severity (for TNF, GG = 4.12; GA = 5.38; AA = 5.50; p = 0.04)
and with morphine-equivalent daily dose (IL-6, GG = 69.61; GC = 93.6; CC = 181.67;
p = 0.004) [36]. An additive effect of mutant alleles in IL1B T-31C (odds ratio =
0.55, 95 % confidence interval = (0.31, 0.97)) was also found to be associated with
high intensity of pain, depressed mood and fatigue in lung cancer patients [31].
In addition to the top connections in the networks, the overall biological processes
involved in the networks help us to better understand the gene-phenotype association.
The IPA core analysis is a process for creating molecule networks on the basis of focus
genes, which are genes associated with the phenotypes of interest. Because all the focus
and non-focus genes in the network have inter-connected relationships, it provides a
list of novel candidate genes associated with the phenotype. The network also provides
a clearer picture of the (possibly interacting) genes that might be directly or indirectly
associated with chemotherapy-induced peripheral neuropathy. The most significant
network generated by IPA core analysis for the focus genes associated with platinum-
induced neuropathy (Fig. 1) contains genes for inflammation (multiple interleukins,
TNF, IFNG, STAT3, STAT1), DNA damage response (TP53) and cell survival (MAPK,
JUN, ERK, NFkB). Network 2, which relates to taxane-induced neuropathy (Fig. 2b), in-
cludes many genes that are involved in the DNA damage response. The network related
to neuropathy induced by combined platinum and taxane therapy (Fig. 3) resembles
Fig. 1 in terms of the cellular functions involved, i.e., inflammation, DNA damage re-
sponse and cell survival. The major commonality among Figs. 1, 2b and 3 is TP53,
which is a central hub in these three networks. Network 1, which relates to taxane-
induced neuropathy (Fig. 2a), primarily involves drug metabolizing enzymes and trans-
porter proteins that will affect the intracellular concentration of taxanes. These analyses
suggest that genetic variations in the DNA damage response are associated with the
risk of developing CIPN, and that taxane-induced neuropathy is also affected by genetic
variations that regulate intracellular drug levels while this aspect may not be important
for platinum compounds.
This bioinformatic approach to expanding gene networks and identifying connec-
tion hubs has limitations. First, many proteins do not interact, while others may con-
nect to major hubs that interact with hundreds of genes and proteins. Therefore, it is
believed that the degree of connectivity obeys a power law, which means that the net-
work is scale-free, a desired property. However, we found that the IPA metric/algo-
rithm that generates networks does not guarantee that the resulting networks are
scale-free, even though the networks may exhibit certain scale-free behavior in which
the major hubs are closely followed by smaller ones that have less connectivity, and
the smaller hubs are then followed by other nodes with an even smaller degree of
connectivity, and so on (see Figs. 1 and 3). Furthermore, the IPA algorithm that
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imum network size (i.e., 140 genes), which might rule out many nodes with small de-
grees of connectivity and impact the scale-free behavior. We employed a widely used
log-log plot to investigate whether the networks in Figs. 1 and 3 follow the power law
[24, 40]. The log-log plot should appear as a decaying straight line if the network obeys the
power law, which was not observed in our plot. Therefore, we cannot conclude that the
resulting networks are scale-free.
Further limitations could be that the connections may be specific to certain tissues or
physiological contexts that are not applicable to CIPN. Many of the connections have not
been demonstrated in neural tissue. Nevertheless, this network analysis identified bio-
logical processes that are relevant to the mechanism of neuropathy induced by platinum
compounds and taxanes, thus providing the basis for future studies of the genes involved
in these biological processes. Our study has not discovered any pathways involved in pain
perception. Perhaps, due to the fact that many studies in the literature were done as focused
search for SNP associations in a relatively small set of genes in pre-selected pathways, such
as glutathione, DNA repair, cell cycle, apoptosis, cell signaling, and metabolism. Whether
new gene sequencing technology can discover genetic markers associated with differences
in neuropathic pain perception remains to be seen. In conclusion, our study has shown
putative genes associated with CIPN. Future studies will include the selection of pharmaco-
genomic panel tests that will help identify patients at risk for CIPN and the routine incorp-
oration of such panels into clinical practice.
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